Representative Lloyd Doggett (D-Texas) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on July 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on June 10th.
Representative Lloyd Doggett also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 6/18/2025.
- Purchased $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 6/12/2025.
- Purchased $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 6/10/2025.
- Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 5/15/2025.
Johnson & Johnson Price Performance
Shares of JNJ traded up $1.09 during mid-day trading on Wednesday, hitting $169.02. 10,616,066 shares of the stock were exchanged, compared to its average volume of 8,168,801. The company has a market cap of $406.67 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm has a 50-day moving average of $155.34 and a two-hundred day moving average of $155.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.82 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's payout ratio is currently 55.61%.
Institutional Trading of Johnson & Johnson
Several hedge funds have recently made changes to their positions in JNJ. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after buying an additional 1,170,120 shares in the last quarter. Geode Capital Management LLC grew its stake in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares in the last quarter. Northern Trust Corp grew its stake in Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after purchasing an additional 130,645 shares in the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. Finally, Wellington Management Group LLP grew its stake in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after purchasing an additional 431,205 shares in the last quarter. Institutional investors own 69.55% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Raymond James Financial reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $172.87.
Read Our Latest Stock Analysis on JNJ
About Representative Doggett
Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas' 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas' 37th Congressional District. He declared candidacy for the 2026 election.
Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett's career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
MarketBeat All Access